Cargando…
Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the USA, has been responsible for significant morbidity and mortality. In May 2021, the Delta variant was upgraded to a variant of concern...
Autores principales: | Landsberg, Hannah E., Turcinovic, Jacquelyn, Sullivan, Madison, Connor, John H., Hamer, Davidson H., Platt, Judy T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556072/ https://www.ncbi.nlm.nih.gov/pubmed/34757200 http://dx.doi.org/10.1016/j.ijid.2021.10.053 |
Ejemplares similares
-
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022) -
Tachycardia following Pfizer-BioNTech COVID-19 vaccine
por: Martins-Filho, Paulo Ricardo
Publicado: (2023) -
Pfizer-BioNTech COVID-19 vaccine safe with clozapine
Publicado: (2022)